Annals of Oncology Advance Access published online on December 1, 2005
Annals of Oncology, doi:10.1093/annonc/mdj067
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
* To whom correspondence should be addressed. Purpose: To assess the feasibility and antitumor activity of oblimersen sodium, an antisense oligonucleotide directed to the Bcl-2 mRNA, combined with irinotecan in patients with advanced colorectal carcinoma, characterize the pharmacokinetic behavior of both oblimersen sodium and irinotecan, and examine Bcl-2 protein inhibition in peripheral blood mononuclear cells (PBMC). Patients and methods: Patients were treated with escalating doses of oblimersen sodium administered by continuous intravenous infusion (CIVI) days 1-8, and irinotecan administered intravenously on day 6 once every 3 weeks. Results: Twenty patients received a total of 84 courses at doses ranging from 3 to 7 mg/kg/day for oblimersen sodium and from 280 to 350 mg/m2 for irinotecan. Febrile neutropenia and diarrhea limited escalation of oblimersen sodium and irinotecan to 5 mg/kg/day and 350 mg/m2, respectively. Other toxicities included nausea, vomiting, fever and fatigue. Steady-state plasma concentrations were achieved within 48 h of beginning oblimersen sodium treatment and the agent was undetectable 24 h after the discontinuation of the infusion. Reduction in levels of Bcl-2 protein in PBMC was documented following treatment with oblimersen sodium. One patient experienced a partial response and 10 additional patients had stable disease lasting 2.5-10 months. Conclusions: The combination is well tolerated at the recommended phase II oblimersen sodium dose of 7 mg/kg/day CIVI days 1-8 with irinotecan 280 mg/m2 intravenously on day 6 every 3 weeks.
Received September 2, 2005
Accepted October 3, 2005
original article
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (GenasenseTM, G3139) and irinotecan in patients with metastatic colorectal cancer
M. M. Mita 1,
L. Ochoa 1,
E. K. Rowinsky 1,
J. Kuhn 2,
G. Schwartz 3,
L. A. Hammond 1,
A. Patnaik 1,
I.-T. Yeh 4,
E. Izbicka 1,
K. Berg 1,
and
A. W. Tolcher 1 *
2 Department of Pharmacology, University of Texas Health Science Center, San Antonio, TX, USA
3 Brooke Army Medical Center, San Antonio, TX, USA
4 Department of Pathology, University of Texas Health Science Medical Center, San Antonio, TX, USA
A. W. Tolcher, E-mail: atolcher{at}idd.org
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. L. Moulder, W. F. Symmans, D. J. Booser, T. L. Madden, C. Lipsanen, L. Yuan, A. M. Brewster, M. Cristofanilli, K. K. Hunt, T. A. Buchholz, et al. Phase I/II Study of G3139 (Bcl-2 Antisense Oligonucleotide) in Combination with Doxorubicin and Docetaxel in Breast Cancer Clin. Cancer Res., December 1, 2008; 14(23): 7909 - 7916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rom, G. von Minckwitz, W. Eiermann, M. Sievert, B. Schlehe, F. Marme, F. Schuetz, A. Scharf, M. Eichbaum, H.-P. Sinn, et al. Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study Ann. Onc., October 1, 2008; 19(10): 1698 - 1705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Liu, J. Kolesar, D. G. McNeel, C. Leith, K. Schell, J. Eickhoff, F. Lee, A. Traynor, R. Marnocha, D. Alberti, et al. A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors Clin. Cancer Res., May 1, 2008; 14(9): 2732 - 2739. [Abstract] [Full Text] [PDF]
|
|